# ISO/IEC 42001:2023 Compliance Matrix
## MedFlow V3 - AI Management System Implementation

**Document ID:** MF-ISO-14
**Title:** ISO/IEC 42001:2023 Compliance Matrix
**Version:** 1.5
**Status:** ACTIVE
**Date:** 2026-02-21
**Author:** Dr. Islam Mekawy
**Reviewer:** Dr. Islam Mekawy (Lead Researcher)
**Approver:** Dr. Islam Mekawy (AI Governance Lead)
**Classification:** CONFIDENTIAL – Internal Use Only
**ISO 42001 Clause:** All Clauses (4–10) + Annex A + Annex B – Master Compliance Reference
**Purpose:** Map MedFlow V3 implementation artifacts to ISO/IEC 42001:2023 requirements
**Supersedes:** MF-ISO42001-MATRIX-001 v1.4 (2026-02-10)

---

## How to Read This Matrix

Each row maps an ISO 42001 clause or Annex A control to a concrete MedFlow artifact. The **Evidence Artifact** column references real files in the project repository. Status values: IMPLEMENTED (control in place), PARTIAL (control exists with known gaps), PLANNED (control designed, not yet operational).

---

## Clause 4: Context of the Organization

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 4.1 Understanding the organization and its context | Determine external/internal issues relevant to the AIMS | Saudi healthcare CDS context defined: MOH protocols, NPHIES data exchange, CHI coding standards, PDPL data sovereignty | `CLAUDE.md` (Project Overview), `MEDFLOW_PROJECT_TRACKER.md` (Technical Decisions Log) | IMPLEMENTED |
| 4.2 Understanding needs and expectations of interested parties | Identify stakeholders and their requirements | 5 stakeholder roles defined: Medical Reviewers, Physicians, Clinical Validators, Data Protection Officers, System Administrators | `iso42001-artifacts/Resource_Management.md` (Section 6.1), `iso42001-artifacts/User_Guide_Clinical.md` | IMPLEMENTED |
| 4.3 Determining the scope of the AIMS | Define boundaries and applicability | Scope: Inpatient admission review CDS for Saudi healthcare insurance. In-scope: LOS decisions, DRG classification, medical necessity. Out-of-scope: Emergency decisions, medication dosing, insurance coverage | `iso42001-artifacts/AIMS_Scope.docx`, `iso42001-artifacts/Algorithmic_Impact_Assessment.md` (Section 2.3) | IMPLEMENTED |
| 4.4 AI Management System | Establish, implement, maintain, and improve the AIMS | 6-layer pipeline architecture with version-controlled components, centralized configuration, and documented lifecycle | `config.py` (MedFlowConfig), `PHASE3_ARCHITECTURE.md`, `iso42001-artifacts/AI_System_Design.md` | IMPLEMENTED |

---

## Clause 5: Leadership

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 5.1 Leadership and commitment | Top management demonstrates commitment to the AIMS | Lead Researcher defined as project architect; AI governance framework established with ISO 42001 alignment from project inception | `CLAUDE.md` (Lead Researcher declaration), `MEDFLOW_PROJECT_TRACKER.md` (Phase overview) | IMPLEMENTED |
| 5.2 AI Policy | Establish AI policy appropriate to the organization's purpose | Medical Necessity policy enforced: system focuses on clinical indication only, never insurance coverage. Private payer references explicitly prohibited | `iso42001-artifacts/AI_Policy.docx`, `gemini_client.py` (SYSTEM_PROMPT medical necessity directive), `CLAUDE.md` (Current Logic Rules) | IMPLEMENTED |
| 5.3 Organizational roles, responsibilities, and authorities | Assign and communicate AIMS roles | 5 roles defined with responsibilities and required skills: System Administrator, AI Engineer, Clinical Validator, Data Protection Officer, Support Engineer | `iso42001-artifacts/Roles_Responsibilities.docx`, `iso42001-artifacts/Resource_Management.md` (Section 6) | IMPLEMENTED |

---

## Clause 6: Planning

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 6.1 Actions to address risks and opportunities | Determine risks/opportunities and plan actions | 15 risks identified across technical and strategic domains, scored by likelihood x impact, with implemented controls and residual risk ratings | `iso42001-artifacts/AI_Risk_Register.md` v4.0 (15 risks, Sections 3-6) | IMPLEMENTED |
| 6.1.2 AI risk assessment | Assess AI-specific risks | AI-specific risks assessed: PII leakage (RISK-001), hallucination (RISK-002), latency (RISK-003), model drift (RISK-010), DRG bias (RISK-007), conflicting AI evidence (RISK-015) | `iso42001-artifacts/AI_Risk_Register.md` v4.0 | IMPLEMENTED |
| 6.1.3 AI risk treatment | Treat identified AI risks | Controls implemented for all 15 risks: Defense-in-Depth PII scrubbing, strict matching, auto-fallback chains, confidence thresholds, human escalation, Dual-Check architecture | `iso42001-artifacts/AI_Risk_Register.md` v4.0 (Control columns per risk) | IMPLEMENTED |
| 6.2 AI objectives and planning to achieve them | Establish measurable AI objectives | Objectives defined: 95% diagnosis accuracy target, 90% recommendation alignment, 0% PII leak rate, <60s/page processing latency | `iso42001-artifacts/AI_Objectives.docx`, `config.py` (SafetyConfig thresholds), `iso42001-artifacts/Verification_Validation_Plan.md` (Section 4.1) | IMPLEMENTED |
| 6.3 Planning of changes | Plan changes to the AIMS in a controlled manner | Version-controlled components (all modules versioned), session-based project tracker, git commit history, technical decisions log with rationale | `MEDFLOW_PROJECT_TRACKER.md` (Technical Decisions Log), git history (4 commits) | IMPLEMENTED |

---

## Clause 7: Support

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 7.1 Resources | Determine and provide resources for the AIMS | Hardware/software/human resource requirements documented: CPU, RAM, GPU specs; Python dependencies; Ollama/Gemini infrastructure; cost estimates | `iso42001-artifacts/Resource_Management.md` v2.0 (Sections 2-5, 10) | IMPLEMENTED |
| 7.2 Competence | Ensure personnel competence for AIMS roles | 5 roles with required skills defined; training requirements specified per role. Competence Assessment Matrix (CAM-001) maps 6 certifications and 16+ yrs experience to 3 AIMS roles — all assessed COMPETENT | `iso42001-artifacts/Resource_Management.md` (Sections 6.1-6.2), `iso42001-artifacts/Competence_Assessment_Matrix.md` (MF-ISO42001-CAM-001) | IMPLEMENTED |
| 7.3 Awareness | Ensure relevant persons are aware of AI policy and AIMS | Clinical User Guide published for medical reviewers; confidence score interpretation guide; override procedures documented | `iso42001-artifacts/User_Guide_Clinical.md` (Sections 3-6) | IMPLEMENTED |
| 7.4 Communication | Determine internal/external AIMS communications | Stakeholder notification framework: patients (admission docs), physicians (portal), hospitals (contract), regulators (annual report) | `iso42001-artifacts/Algorithmic_Impact_Assessment.md` (Section 7) | IMPLEMENTED |
| 7.5 Documented information | Create and maintain AIMS documentation | 13 ISO artifacts maintained: 4 DOCX governance docs + 7 MD technical docs + CLAUDE.md + PROJECT_TRACKER. Version-controlled with revision history | `iso42001-artifacts/` (11 files), `CLAUDE.md`, `MEDFLOW_PROJECT_TRACKER.md` | IMPLEMENTED |

---

## Clause 8: Operation

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 8.1 Operational planning and control | Plan, implement, and control processes to meet AIMS requirements | 8-step CDS pipeline with centralized orchestration: PII scrub, merge, summarize, timeline, guidelines, DRG validation, decision, assembly. Pipeline reordered (CCAP Phase C): DRG runs BEFORE decision so severity context flows into clinical reasoning. Escalation criteria codified: Severity A + WORSENING → ESCALATE, confidence <0.40 → ESCALATE. **NC-005 Fix B/C (CLOSED):** Step 2 injects document type metadata headers during merging. Step 2.5 pre-Gemini timeline engine extracts dates from structured fields, overrides Gemini LOS. Document type context injected into decision prompt. Validated via 30-day Masterpiece case. | `cds_brain.py` v1.4.0 (metadata-aware merging, pre-Gemini timeline, doc type context), `config.py` (ProcessingConfig), `output/masterpiece_result.json` | IMPLEMENTED |
| 8.2 AI system impact assessment | Conduct impact assessments for AI systems | Algorithmic Impact Assessment covering 3 dimensions: Patient Safety (3 risks), Fairness/Bias (3 concerns), Human Oversight (4-tier framework). **NC-002 CLOSED:** Fairness test suite executed (`fairness_test.py`): 32 demographically-stratified cases, 24/24 fairness metrics PASS (0.00% variance). Evidence: `Algorithmic_Fairness_Report.md` (AFR-001) | `iso42001-artifacts/Algorithmic_Impact_Assessment.md` v1.0, `iso42001-artifacts/Algorithmic_Fairness_Report.md` v1.0, `fairness_test.py` | IMPLEMENTED |
| 8.3 AI system life cycle processes | Manage AI system through its lifecycle | 5-layer architecture with versioned components, defined development phases (1-5.5), modular design enabling independent component updates | `iso42001-artifacts/AI_System_Design.md` v2.0, `PHASE3_ARCHITECTURE.md` | IMPLEMENTED |
| 8.4 Data management for AI systems | Manage data quality, provenance, and preparation | Data classification (4 tiers: PHI/PII/Clinical/Operational), PII extraction strategy, strict matching policy, data localization controls, retention periods (7-year). **CCAP Phase A:** Synthetic test data clinically validated — age-stratified diagnosis pools, locked patient data across reports, diagnosis-specific PE/imaging/labs, clinical disposition logic. **NC-005 Fix A (CLOSED):** PE generation fallback uses NEUTRAL_PE (non-pathological defaults). **V3.0 Engine:** Arc-based clinical simulation with vitals curves, lab kinetics, medication state machine, PE evolution for coherent multi-day trajectories. | `iso42001-artifacts/AI_Data_Policy.md` v1.0 (Sections 2-7), `synthetic_data.py` v3.0.0 (V3.0 Clinical Simulation Engine), `iso42001-artifacts/Internal_Audit_Report.md` (NC-004 + NC-005 CLOSED) | IMPLEMENTED |
| 8.5 AI system monitoring and control | Monitor AI system performance during operation | Health check system (Ollama, Gemini, KB, DRG statuses), processing time tracking, confidence score monitoring, auto-fallback on API failures. **CCAP Phase B:** 5-tier confidence calibration enforced in Gemini prompts (0.90+ textbook → <0.40 critical-missing). Input truncation removed — full clinical text sent to Gemini 1M context. **CCAP Phase D:** Dashboard displays precise confidence with threshold context, flags out-of-range values, warns on dropped timeline events | `cds_brain.py` v1.3.0 (--health flag), `app.py` (sidebar health status), `gemini_client.py` v2.0.0 (calibration, no truncation), `dashboard_utils.py` v1.3.0 (safety warnings) | IMPLEMENTED |
| 8.6 Third-party and customer relationships | Manage external AI system providers | Gemini API as sole cloud dependency; anonymized data only; API encryption; no PII sharing; prohibited actions documented | `iso42001-artifacts/AI_Data_Policy.md` (Sections 8-9), `gemini_client.py` (API integration) | IMPLEMENTED |

---

## Clause 9: Performance Evaluation

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 9.1 Monitoring, measurement, analysis, and evaluation | Monitor and measure AIMS performance | Automated test suites: DRG Validator (8/8 pass), KB strict matching (6/6 pass), PII CLI test, system health check. Processing metrics in CaseResult metadata. **CCAP Phase E:** Full pipeline re-validation 5/5 cases clinically appropriate | `iso42001-artifacts/Verification_Validation_Plan.md` v2.0 (Sections 3, 5), `drg_validator.py` v1.1.0 (--test), `knowledge_base.py` (--test-strict), `iso42001-artifacts/Continual_Improvement_Log.md` (IMP-015 Phase E results) | IMPLEMENTED |
| 9.1.2 Analysis of AI system performance | Analyze AI system outputs for quality | End-to-end pipeline tests documented: Complex Sepsis case (DRG upcoding detected), Messy DKA case (contradictory documentation flagged), 5 saved cases crash-free. **CCAP Phase E validation:** AKI→EXTENSION(95%), Appendicitis→DISCHARGE(88%), Appendicitis+cardiac→ESCALATE(95%), Sepsis→EXTENSION(88%), CHF→EXTENSION(95%). Confidence calibration producing meaningful differentiation (50-95% range) | `iso42001-artifacts/Verification_Validation_Plan.md` (Sections 5.2-5.3), `output/` (saved case results), `iso42001-artifacts/Internal_Audit_Report.md` (NC-004 CCAP Phase E evidence) | IMPLEMENTED |
| 9.2 Internal audit | Conduct internal AIMS audits | PII Manifest audit trail per case (SHA-256 hashes, detection counts, layer breakdown), CaseResult metadata (model used, timestamps, confidence), dashboard audit section. Internal Audit conducted (MF-ISO42001-IAR-001): 39 controls, 4 NCs raised (NC-001 CLOSED, NC-002 OPEN, NC-003 OPEN, NC-004 CLOSED via 5-phase CCAP) | `pii_scrubber.py` (PIIManifest generation), `dashboard_utils.py` (render_pii_audit, render_processing_audit), `iso42001-artifacts/Internal_Audit_Report.md` | IMPLEMENTED |
| 9.3 Management review | Review AIMS at planned intervals | Session-based project tracking (10 sessions), phase gate reviews, technical decisions log with rationale and date | `MEDFLOW_PROJECT_TRACKER.md` (Session Log, 10 sessions), `iso42001-artifacts/AI_Risk_Register.md` (revision history) | IMPLEMENTED |

---

## Clause 10: Improvement

| ISO 42001 Clause | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| 10.1 Continual improvement | Continually improve AIMS suitability, adequacy, and effectiveness | Iterative optimization across phases: PII extraction strategy (3-5x speedup), strict matching controls, DRG Dual-Check architecture, dashboard hardening (15 guards). **NC-004 CCAP:** 28-finding clinical pipeline remediation across 5 phases — the most comprehensive improvement action to date (IMP-015) | `MEDFLOW_PROJECT_TRACKER.md` (Sessions 5, 7, 9, 13), `pii_scrubber.py` v2.1.0, `knowledge_base.py` v1.4.0, `iso42001-artifacts/Continual_Improvement_Log.md` (IMP-015) | IMPLEMENTED |
| 10.1.2 Nonconformity and corrective action | Address nonconformities and take corrective action | Root cause analysis documented: "Hypoglycemia Magnet" bug (substring matching), severity marker regex bug, Gemini model fallback failures. **NC-004 CCAP (Major NC):** 28 clinical non-conformities across 6 pipeline layers. 5-phase corrective action: synthetic data validity, Gemini prompt engineering, DRG-decision integration, dashboard safety, full re-validation. NC-001 closed (competence matrix). NC-004 closed (CCAP 5/5 validation pass) | `iso42001-artifacts/AI_Risk_Register.md` (RISK-002 Root Cause Analysis), `iso42001-artifacts/Internal_Audit_Report.md` (NC-004), `MEDFLOW_PROJECT_TRACKER.md` (Sessions 5, 13) | IMPLEMENTED |
| 10.2 Continual improvement of AI systems | Improve AI system performance and trustworthiness | Gemini fallback chain (3+ models), confidence threshold tuning (85%/70%/40%), STOP_WORDS filter evolution, 4-lens terminology standardization for regulatory alignment. CCAP improvements: 5-tier confidence calibration, DRG→decision integration, primary diagnosis weighting, threshold-aligned terminology labels | `gemini_client.py` v2.0.0 (MODEL_FALLBACK_ORDER, calibration), `config.py` (SafetyConfig), `terminology_system.py` v1.1.0, `knowledge_base.py` (STOP_WORDS), `drg_validator.py` v1.1.0 (primary diagnosis weighting) | IMPLEMENTED |

---

## Annex A: Reference Controls

| Annex Control | Requirement | MedFlow Implementation | Evidence Artifact | Status |
|---|---|---|---|---|
| A.2 AI Policy | Establish policies for responsible AI use | Medical Necessity policy; private payer prohibition; guideline hierarchy (MOH > UpToDate > General Clinical Reasoning) | `iso42001-artifacts/AI_Policy.docx`, `CLAUDE.md` (Current Logic Rules) | IMPLEMENTED |
| A.3 Internal Organization | Define AI governance structure | 5 roles with RACI-style responsibilities; Lead Researcher as system owner and architect | `iso42001-artifacts/Roles_Responsibilities.docx`, `iso42001-artifacts/Resource_Management.md` (Section 6) | IMPLEMENTED |
| A.4 Resources for AI Systems | Provision adequate resources | Hardware specs (CPU/RAM/GPU), software stack (Python, Ollama, Gemini), infrastructure costs documented | `iso42001-artifacts/Resource_Management.md` v2.0 (Sections 2-5, 10) | IMPLEMENTED |
| A.5 AI System Impact Assessment | Assess impacts of AI systems | 3-dimension AIA: Patient Safety, Fairness/Bias, Human Oversight. Residual risk ratings. Stakeholder notification plan | `iso42001-artifacts/Algorithmic_Impact_Assessment.md` v1.0 | IMPLEMENTED |
| A.6 AI System Life Cycle | Manage development and operation | 6-phase lifecycle (Foundation > Local AI > CDS > DRG > Dashboard > ISO Implementation), version-controlled modules, modular architecture. CCAP demonstrated lifecycle corrective action capability: identified 28 clinical non-conformities, executed 5-phase remediation, validated with 5/5 clinical cases | `iso42001-artifacts/AI_System_Design.md` v2.0, `MEDFLOW_PROJECT_TRACKER.md` (13 sessions), `iso42001-artifacts/Internal_Audit_Report.md` (NC-004 lifecycle) | IMPLEMENTED |
| A.7 Data for AI Systems | Govern data used by AI systems | Data classification, PII handling, PDPL localization, data quality controls, retention policies, incident response protocol | `iso42001-artifacts/AI_Data_Policy.md` v1.0 | IMPLEMENTED |
| A.8 Information for Interested Parties | Provide transparency about AI systems | Transparency statement in AIA; Clinical User Guide for reviewers; confidence score explanations; override procedures; appeal pathways | `iso42001-artifacts/Algorithmic_Impact_Assessment.md` (Section 7.2), `iso42001-artifacts/User_Guide_Clinical.md` | IMPLEMENTED |
| A.9 Use of AI Systems | Ensure appropriate use of AI outputs | 4-tier review framework (Autonomous/Supervised/Escalated/Emergency); override mechanisms; documented rationale requirements; appeal pathway | `iso42001-artifacts/Algorithmic_Impact_Assessment.md` (Section 5), `iso42001-artifacts/User_Guide_Clinical.md` (Sections 5-6) | IMPLEMENTED |
| A.10 Third-party Relationships | Manage external AI providers | Gemini API: anonymized data only, HTTPS encryption, no PII transfer. Prohibited actions documented. Incident response for API compromise | `iso42001-artifacts/AI_Data_Policy.md` (Sections 8-9), `gemini_client.py` | IMPLEMENTED |

---

## Compliance Summary

| ISO 42001 Area | Total Controls | Implemented | Partial | Planned |
|---|---|---|---|---|
| Clause 4: Context | 4 | 4 | 0 | 0 |
| Clause 5: Leadership | 3 | 3 | 0 | 0 |
| Clause 6: Planning | 5 | 5 | 0 | 0 |
| Clause 7: Support | 5 | 5 | 0 | 0 |
| Clause 8: Operation | 6 | 6 | 0 | 0 |
| Clause 9: Evaluation | 4 | 4 | 0 | 0 |
| Clause 10: Improvement | 3 | 3 | 0 | 0 |
| Annex A Controls | 9 | 9 | 0 | 0 |
| **TOTAL** | **39** | **39** | **0** | **0** |

**Overall Compliance Rate: 100% Implemented (39/39)**

**Previously Partial (Cl. 7.2 Competence):** Resolved 2026-02-09 — Competence Assessment Matrix (MF-ISO42001-CAM-001) created with full evidence of qualifications per role. NC-001 closed.

**NC-004 (Major) Clinical Output Validity:** Resolved 2026-02-10 — 5-phase CCAP completed. 28 clinical non-conformities across 6 pipeline layers remediated. 5/5 validation cases clinically appropriate. Evidence: `synthetic_data.py` v2.0.0, `gemini_client.py` v2.0.0, `cds_brain.py` v1.3.0, `drg_validator.py` v1.1.0, `dashboard_utils.py` v1.3.0, `terminology_system.py` v1.1.0.

**NC-005 (Major) Clinical Logic Failure & Timeline Inconsistency:** Resolved 2026-02-10 — 3-fix remediation validated via 30-day Sepsis Masterpiece case (11 documents, 121 PII items, DISCHARGE 95% AUTO_APPROVED, 6-day delay correctly identified). Fixes: (A) `synthetic_data.py` v3.0.0 neutral PE fallback + V3.0 Clinical Simulation Engine, (B) `cds_brain.py` v1.4.0 metadata-aware merging + doc type context, (C) `cds_brain.py` v1.4.0 pre-Gemini timeline engine. Clauses 8.1 and 8.4 restored to IMPLEMENTED. NC-005 **CLOSED**.

**NC-003 (Minor) Automated Drift Detection:** Resolved 2026-02-16 — Real-Time Risk Monitor (RTRM) v1.0.0 implemented in `governance/real_time_risk_monitor.py`. 2-signal drift detection (confidence distribution + recommendation distribution), >10% threshold, 100-event rolling window. 51-case gold standard dataset (12 diagnoses, 4 clinical arcs). 11/11 automated tests PASS. NC-003 **CLOSED**. All 5 NCs now CLOSED.

---

## Document Approval

| Role | Name | Date | Signature |
|---|---|---|---|
| Lead Implementer | Dr. Islam Mekawy | 2026-02-10 | __________ |
| Internal Auditor | _________________ | __________ | __________ |

---

## Revision History

| Version | Date | Author | Changes |
|---|---|---|---|
| 1.0 | 2026-02-08 | Dr. Islam Mekawy | Initial compliance matrix (39 controls mapped) |
| 1.1 | 2026-02-10 | Dr. Islam Mekawy | Updated for NC-004 CCAP closure: Clauses 8.1, 8.4, 8.5, 9.1, 9.2, 10.1, 10.2, A.6 evidence updated with CCAP phase results and module versions |
| 1.2 | 2026-02-10 | Dr. Islam Mekawy | NC-005 (Major): Clauses 8.1 and 8.4 set to PARTIAL. 3-fix remediation referenced (synthetic_data.py v2.1.0, cds_brain.py v1.4.0). Summary: 36/39 implemented, 3 partial. |
| 1.3 | 2026-02-10 | Dr. Islam Mekawy | NC-005 CLOSED via Masterpiece validation. Clauses 8.1, 8.4 restored to IMPLEMENTED. Cl.7.2 corrected to IMPLEMENTED (NC-001 closed). synthetic_data.py updated to v3.0.0 (V3.0 engine). Summary: 39/39 implemented (100%). |
| 1.4 | 2026-02-10 | Dr. Islam Mekawy | NC-002 CLOSED via fairness testing. Clause 8.2 evidence updated with AFR-001 and fairness_test.py. |
| 1.5 | 2026-02-16 | Dr. Islam Mekawy | NC-003 CLOSED: RTRM v1.0.0 deployed with 2-signal drift detection, 51-case gold standard, 11/11 tests PASS. All 5 NCs now CLOSED. |

---

*End of Document*
